Radioligand Therapy Hormone Combinations and the ENZA-p Trial - PubMed
2 hours ago
- #PSMA radioligand therapy
- #enzalutamide combination
- #ENZA-p trial
- The androgen axis drives prostate cancer growth, making androgen blockade a cornerstone treatment for metastatic prostate cancer.
- PSMA radioligand therapy is increasingly important in treating metastatic castration-resistant prostate cancer (mCRPC), with strong interactions between androgen and PSMA receptors observed in clinical and preclinical studies.
- The ENZA-p trial, a randomized phase 2 study, showed that combining enzalutamide with lutetium-177 ([177Lu])Lu-PSMA-617 significantly improves overall survival and quality of life compared to enzalutamide monotherapy in mCRPC.
- Translational endpoints in the ENZA-p trial aim to understand the relationship between androgen blockade and PSMA expression, exploring the genetics of PSMA expression and its changes in response to enzalutamide.